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Targeting the MAPK pathway by combined inhibition of BRAF and MEK has increased overall 
survival in advanced BRAF-mutant melanoma in both therapeutic and adjuvant clinical 
settings. However, a significant proportion of tumors develop acquired resistance, leading to 
treatment failure. We have previously shown p63 to be an important inhibitor of p53-induced 
apoptosis in melanoma following genotoxic drug exposure. Here we investigated the role of 
p63 in acquired resistance to MAPK inhibition and show that p63 isoforms are upregulated in 
melanoma cell lines chronically exposed to BRAF and MEK inhibition, with consequent 
increased resistance to apoptosis. This p63 upregulation was the result of its reduced 
degradation by the E3 ubiquitin ligase FBXW7. FBXW7 was itself regulated by MDM2, and in 
therapy-resistant melanoma cell lines, nuclear accumulation of MDM2 caused downregulation 
of FBXW7 and consequent upregulation of p63. Consistent with this, both FBXW7 inactivating 
mutations and MDM2 upregulation were found in melanoma clinical samples. Treatment of 
MAPK inhibitor-resistant melanoma cells with MDM2 inhibitor Nutlin-3A restored FBXW7 
expression and p63 degradation in a dose-dependent manner and sensitized these cells to 
apoptosis. Collectively, these data provide a compelling rationale for future investigation of 
nutlin-3A as an approach to abrogate acquired resistance of melanoma to MAPK inhibitor 




Upregulation of p63, an unreported mechanism of MAPK inhibitor resistance in melanoma, 
can be abrogated by treatment with the MDM2 inhibitor Nutlin-3A, which may serve as a 







Advanced melanoma is an aggressive cancer. Discovery of the oncogenic mutation 
BRAFV600E led to development of targeted BRAF inhibitors, which have significantly 
prolonged overall survival and progression-free in advanced melanoma (1). Combined BRAF 
and MEK targeted therapy increases the rate and durability of treatment responses and this 
combination therapy is now used in both therapeutic and adjuvant clinical settings (2). 
However, despite initially impressive clinical responses, most patients with advanced 
melanoma treated with MAPK inhibitors develop acquired resistance within 6 to 7 months (3). 
Resistance is an important clinical challenge and understanding the mechanisms of resistance 
is currently an area of intense research activity.  
TP63 is critical for the development and maintenance of squamous epithelia. It is mainly 
expressed in the basal layers of stratified epithelial tissues where is considered a cell lineage 
specific marker (4). TP63 has been linked to chemosensitivity in a number of tumours and is a 
biomarker for poor prognosis in breast cancer and follicular cell lymphoma (5) (6). We 
previously provided the first evidence supporting an oncogenic role for p63 in melanoma. We 
reported up-regulation of p63 mRNA and protein in melanoma and induction of p63 nuclear 
stabilization and partial relocation to the mitochondria in response to DNA-damaging agents. 
Consequently, p63 has an anti-apoptotic role in melanoma, contributing to chemoresistance 
and its expression correlates with melanoma-specific death (7). 
Multiple ligases degrade p63 in keratinocytes. This include E3 ubiquitin ligases (Nedd4, Itch 
and its homologue WWP1) and Ubc9, a SUMO-conjugating enzyme. Pirh2 (p53-induced 
RING-H2) also modulates keratinocyte differentiation by targeting both TA and ΔNp63 for 
proteasomal degradation (8-16).  
FBXW7 is a E3 ubiquitin ligase which contributes to p63 degradation in keratinocytes (17) and 
functions as a potent tumour suppressor with many oncoprotein targets. FBXW7 is also 
mutated in about 8% of melanomas and is inactivated in about 40% of melanoma cell lines 
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(18). In keratinocytes, MDM2 and FBXW7 cooperatively control the stability of p63 protein 
during keratinocyte differentiation and UV irradiation. MDM2 binds with ∆Np63 and transports 
it into the cytoplasm where its phosphodegron domain is recognized by FBXW7 (17). HDAC 
inhibitors (HDACi) reduce ∆Np63 protein levels via FBXW7 E3 ubiquitin ligase (19).FBXW7 is 
alternatively spliced to produce three C-terminal isoforms, alpha, beta and gamma (20-24). 
The cellular localization signal is in the C-terminal variable region, while the N-terminal region 
includes seven WD40 domain, which recognizes and binds with its target protein, and is 
conserved between different isoforms. Several inactivating mutations are reported in this 
WD40 region, which selectively loses the capacity to target specific protein in human tumours 
(25-28).  
MDM2 and MDM4 are potent oncogenes and are commonly over-expressed in cancer, 
including melanoma. They are well-known inhibitors of p53 and in normal tissues maintain p53 
at reduced intracellular levels by mediating its rapid degradation and subsequently inhibiting 
its transcriptional activity (29-32). P53 mutations are common in many UV-associated skin 
cancers (33), but are less common in melanoma, present in up to 19% as a point mutation, 
and in the remaining wild type (wt) tumours, p53 is often inactivated by other mechanisms 
(34), such as MDM2 amplification. 
MDM2 and MDM4 amplification, although mutually exclusive, are often involved in 
mechanisms of wild type p53 inactivation in melanoma (35-38) and targeting MDM2 is a 
recognised therapeutic approach in wt TP53 cancers. Nutlin-3A, a small molecule MDM2 
inhibitor, prevents its association with p53 leading to wt p53 accumulation and reactivation 
(39). Nutlin-3A also stabilizes p73 and stimulates p53 independent pro-apoptotic activities 
(40). Nutlin-3A is currently used as an anti-tumour agent both in vitro and in vivo, targeting 
solid tumours including melanoma, breast cancer, prostate cancer, retinoblastoma and 
haematological malignancies (41). Nutlin-3A treatment downregulates IGF-1R protein levels 
by stabilizing MDM2 and increases migratory capacity of melanoma cells via ERK activation, 
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although reduces their invasive potential by destabilizing MAPK/PI3K balanced activation 
leading to disrupted IGF-1R - MMP2 activation (42). 
Here we investigate a possible role for p63 involvement in acquired resistance to MAPK 
inhibition, characterising p63 expression and mechanisms of p63 regulation upon acquisition 
of MAPK inhibitor resistance. We also provide a rationale for the use of Nutlin-3A as an 
approach to reducing acquired resistance associated with therapeutic MAPK inhibition in 
melanoma. 
MATERIAL AND METHODS 
Cell culture. HaCaT, HCT116 and HEK293T cells were cultured in DMEM medium 
supplemented with 10% FCS and 1% pen/strep antibiotic solution. All melanoma cell lines 
were cultured in RPMI-1640 medium supplemented with 10% foetal calf serum (FCS) and in 
antibiotic free conditions. Establishment of vemurafenib or Trametinib resistant melanoma 
cells was performed on BRAFV600E mutated cell lines seeded and treated with increasing 
doses of PLX4032 or Trametinib for at least 1 month. Media with fresh drug was replaced 
every other day and cells were split when necessary. Afterwards PLX4032 drug dose was 
maintained to 3μM and Trametinib for 50nM. Cells were used in further experiments only after 
the resistance was confirmed. Cell lines LM16, LM17 and LM36 (sensitive and PLX-resistant) 
kindly provided by Dr Monica Rodolfo, where established in another laboratory following 
similar procedure.  
Protein extraction and western blotting. Equal amount of protein lysates was resuspended 
in 10X NuPage reducing agent (500mM DTT, Invitrogen #NP0009) and 4X NuPage Lithium 
dodecyl sulphate (LDS) sample buffer (Invitrogen # NP0007). Samples were mixed and 
heated at 70°C for 10 minutes. Protein samples were resolved using 10% Bis-Tris gels. The 
fast transfer was performed using the BioRad Trans-Blot® Turbo™ RTA Mini PVDF Transfer 
Kit (#1704274) with Trans-Blot® Turbo™ system at 25A and 2.5V for 10 minutes. Upon 
completion of protein transfer, the membrane was washed with dH2O and left for blocking for 1 
hour with 5% BSA (Sigma). The membrane was incubated with primary antibody at +4°C for 
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overnight. The next day, after 3 x 10 minutes PBS Tween-20 0.1% (PBST) washings, the 
membrane was incubated with anti-mouse antibody (DAKO) diluted 1:5000 (vol/vol) or anti-
rabbit antibody (DAKO) diluted 1:10000 (vol/vol) in PBST supplemented with 1% BSA for 1 
hour at room temperature. The membranes were washed three times with PBS-Tween 0.1%, 
and bound secondary antibody was detected by enhanced chemiluminescence with ECL Plus 
(GE Healthcare) according to the manufacturer’s protocol. For cytoplasmic and nuclear protein 
extraction, cells pellet was resuspended in 300µl hypotonic buffer. Later mixed with 25µl 10% 
NP40 (detergent) reagent and vortexed for 20 seconds followed by 10 minutes centrifugation 
at 3000 rpm at 4ºC. Then carefully supernatant was collected in separate tube labelled as 
cytoplasmic fraction. The nuclear pellet was gently washed twice with ice-cold PBS to avoid 
the contamination from cytoplasmic fraction. Nuclear pellet was resuspended in 50µl complete 
Cell Extraction buffer (#FNN0011, Thermo-Fisher) followed by 30 minutes incubation on ice 
with vortexing at every 10 minutes intervals. The cells debris was removed by 30 minutes 
centrifugation at full speed at 4ºC. The supernatant (nuclear fraction) was collected into a 
clean microcentrifuge tube. These both fractions were analysed on SDS-PAGE as previously 
described. Antibodies used: p63 (#SFI-6, DSC Diagnostics Germany), p63 (#M731729-2, 
Dako, Agilent Technologies LDA UK Limited) p63 (#H137, Santa Cruz), GAPDH (Generon), 
MDM2 (#N20, Santa Cruz), FBXW7 (#109617, abcam). 
In vitro ubiquitination assay. In vitro ubiquitination assay performed with Abcam (ab139469) 
kit using purified recombinant FBXW7 protein. As per the kit protocol, two control reactions 
(without ATP or MDM2) and final reactions with recombinant FBXW7 mixed together. The 
reactions were incubated at 37°C for 90 minutes and terminated with 2x SDS-PAGE gel 
loading buffer followed by heating at 95°C. The reaction products were subsequently analysed 
by SDS-PAGE and chemiluminescent western blot. 
shRNA. Genes were stably silence using pLKO.Puro lentiviral system. For p63: 
GAAGAAACTCTACTGCCAAAT, GAATTCAACGAGGGACAGATT and for FBXW7: 
GCAACAACGACGCCGAATTAC, GGACTCCTCAGGAAACCAAGA and scramble: 
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TGTTATACGATTTCCTGCACC sequences were cloned in pLKO.Puro vector according to 
Addgene protocol. pLenti-puro was a gift from Ie-Ming Shih (Addgene plasmid # 39481). 
DNA mutation analysis. Paraffin embedded tissues derived from each lesion were macro-
dissected and DNA was isolated by using QIAamp DNA micro Kit (Qiagen). BRAF exon 15 
and NRAS exons 2 and 3 were amplified by previously optimized PCR primers and conditions. 
PCR products were purified by ExoSAP-IT (USB Corporation, Cleveland, Ohio) and 
sequenced using Big Dye Terminator V3.1 Cycle Sequencing Kit on AB3500dx DNA Analyzer 
(Life Technologies). Sequence analysis was performed by Variant Reporter (Life 
Technologies).  
Immunohistochemistry. Paraffin embedded tissue samples material representing different 
stages of melanoma development analysed in this study were obtained from Barts and the 
London NHS Trust. The investigators obtained informed written consent from the patients. All 
patients’ data collected and used in the manuscript has been consented with an institutional 
review board-approved protocol that allows comprehensive analysis of tumour samples and 
covered by an ethical approval [07/QO604/23 by the East London & The City HA Local 
Research Ethics committee 2, UK]. Tissue samples were fixed in 10% formal saline solution 
before being embedded in paraffin wax. 3-4 µm sections were mounted onto a positively 
charged slide, dewaxed in xylene twice for 3 min and rehydrated in alcohol twice for 3 min 
before being placed in running water for 5 min. Antigen retrieval for p63 staining, slides were 
microwaved in Tris-EDTA unmasking solution pH9 for 35 min. Following antigen retrieval 
sections were placed in running water for 5 min before endogenous peroxidase activity was 
blocked by incubation with 3% hydrogen peroxide solution for 15 min. Sections were washed 
three times in wash buffer before Normal Horse Serum (Vector R.T.U. kit, Vector Labs) was 
applied for 20 min. The serum was then replaced by primary antibody diluted in antibody 
diluent to the appropriate concentration. Negative control sections were treated with antibody 
diluent without antibody. Sections were incubated at room temperature for 1 h then washed 3 
times in wash buffer. Universal Biotinylated Secondary Antibody (Vector R.T.U. kit) was added 
for 30 min, sections were washed in wash buffer twice then incubated with Vectastain Elite 
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ABC Reagent (Vector R.T.U. kit) for 30 min. Sections were washed 3 times with wash buffer 
then incubated for 5 min with DAB solution before being washed in running water for 5 min. 
The clinical samples labelled for p63, FBXW7 and MDM2 were reviewed by three independent 
scorers, blinded to any clinical details of the patients. 
Immunofluorescence staining of tissue sections. Paraffin-embedded tissue samples of 
melanoma patients before and after acquisition of MAPKi resistance were kindly provided by 
Dr Christian Posch. After hydration of paraffin-embedded tissue in a xylene-alcohol series 
antigen-retrieval was done in Citric Buffer and left to cool down to room temperature. Samples 
were washed, covered by blocking buffer in a humidity chamber and then incubated with 
primary antibodies (MART-1 from Signalway Ab and SFI-6 against p63 from DSC Diagnostics 
Germany), diluted in blocking buffer and incubated over night at 4°C in a humidity chamber. 
The next day, excess primary antibody was removed with 3 washes and samples were 
incubated with the appropriate fluorophore-coupled secondary antibody, against the antigen of 
the primary antibody (1:800 in Blocking Buffer, 1.5h, RT). This was followed by 3 washes and 
the staining of the nuclei with 4', 6-diamidino-2-phenylindole (DAPI) (1:1000 in PBS, 5 min, 
RT). Excess DAPI was removed with one wash in PBS (5min, RT). Coverslips were mounted 
on the slides with the sections using Immu-Mount (Thermofisher) to preserve the 
immunofluorescence staining. Images of stained samples were then acquired with an INCell 
2200 automated microscope using both 4x and 20x objectives. 4x objective fields were taken 
with a 15% overlap to allow image stitching and to provide a section overview. All images 
have been contrasted based on a negative control. 
Immunocytochemistry. Cells were seeded onto coverslips and fixed the following day in 4% 
formaldehyde for 10 min followed by two 5 min washes in PBS. Cell membranes were 
permeabilised in 0.3% Triton X-100 for 2 min at RT coverslips were then washed twice with 
PBS. Cells were incubated with 5% goat serum/PBS for 30 min. After removal of the serum, 
cells were incubated with primary antibody diluted in 5% goat serum/PBS overnight at 4°C. 
Cells were washed 3 times for 10 min in PBS before being incubated with secondary antibody 
dilution 1/500 in 5% PBS/goat serum) for 1h at RT in the dark. Cells were washed twice for 10 
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min in PBS then incubated with 4',6-diamidino-2-phenylindole (DAPI) for 10 min followed by 
two washes in PBS for 10 min. Coverslips were mounted onto a glass slide and stored at 4˚C 
protected from light. 
Annexin-V Binding assay. To induce apoptosis, cells were treated with different drugs for 24 
h. After treatment adherent cells and any cells in supernatants were collected and pelleted 
before being washed in PBS. Cells were resuspended in 400μl 1X Becton Dickinson Annexin 
V Binding Buffer (BD Pharmingen™) and processed according to the manufacturer’s 
instructions. Results were analysed using the Becton Dickinson FACSDiva software. 
RESULTS 
p63 expression significantly correlates with BRAF and NRAS mutational status in 
melanoma. 
We have previously shown that expression of oncogenic p63 correlates with worse outcome in 
melanoma (7), but the association between p63 expression and BRAF/NRAS mutational 
status has not yet been established. A panel of 50 melanomas previously analysed for p63 
expression (Figure 1A) were macro-dissected and genotyped for BRAF (exon 15) and NRAS 
(exons 2-3) mutational status. We identified a significant correlation between p63 expression 
and mutation in BRAF and NRAS (Figure 1B and Table1), supporting a similar correlation in 
established melanoma cell lines at both gene (Suppl Figure S1B) and protein levels (Figure 
1C). Validation with an independent melanoma dataset from The Cancer Genome Atlas 
(TCGA) (43) confirmed an association (although not statistically significant) between 
increased p63 expression and BRAF and NRAS mutational status (Suppl Figure S1A). 
In order to test whether p63 expression affects MAPK activation, p63 isoforms were transiently 
expressed in p63 null melanoma cell lines (Mel 224 and LM1) and resulted in increased 
expression of phosphorylated MEK1/2 (Figure 1D). Conversely silencing of endogenous p63 
in a BRAFV600E melanoma cells (A375M) significantly reduced expression of phosphorylated 
MEK1/2 (Figure 1E). Overexpression of p63 ΔNβ isoform in WM164 cells significantly 
increased EGFR expression and affected phosphorylation activity. EGFR upregulation, 
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already reported in melanoma cell lines resistant to BRAF inhibition (44), resulted in increased 
phosphorylated MEK1/2 expression (Figure 1F). EGFR inhibition abolished p63-driven effects 
on phospho-MEK1/2 expression, suggesting that p63 can influence MAPK signalling via 
EGFR in melanoma cells. 
Development and characterization of MAPK inhibitor resistant cell lines. 
Cellular models were established to investigate the consequences of p63 expression in 
MAPKi-resistant melanomas. Five BRAF-inhibitor (BRAFi) resistant (WM1158, WM793, 
A375M, WM278 and WM164) and 2 MEK inhibitor (MEKi) resistant (A375M, WM164) 
melanoma cell lines were chronically treated three times a week for 10-12 weeks with 2µM 
PLX4032 (vemurafenib) and 50nM trametinib, respectively, until they acquired resistance. 
Major changes in cell shape, plasticity and size were observed: WM793-PLX and WM278-PLX 
cells became very elongated and acquired phenotypic features of mesenchymal cells; 
conversely WM1158-PLX cells transformed from mesenchymal-like to an epithelial-like 
morphology (Suppl. Figure S1C). Trametinib-resistant cells increased their size and become 
very large and multinucleated. These morphological changes were driven by a cytoskeleton 
reorganization with significant changes in actin fibers polarization and angle dispersion (Suppl. 
Fig S1D-E). To confirm the acquisition of BRAF or MEK inhibitor resistance, cells were treated 
with vemurafenib (3µM and 6µM) or with trametinib (50nM) for 24h. Expression of 
phosphorylated MEK and ERK was significantly decreased in BRAFi and MEKi sensitive cell 
lines whereas high dose vemurafenib or trametinib had no effect on MEK and ERK 
phosphorylation in MAPKi resistant cells (Figure 2A-C and Suppl. Figure S1F-G).  
Resistance to BRAF inhibitors was further tested by measuring cell viability of resistant and 
sensitive cell lines after 24 hours of increasing concentration of vemurafenib. All cell lines 
tested showed significantly increased cell survival with vemurafenib compared to their 
sensitive counterpart (Figure 2D). Growth curves revealed significant lower cell proliferation in 
BRAFi and MEKi resistant cells (Figure 2E and Suppl. Figure S1H). High expression levels of 
CD271 have been associated with metastatic progression, enhanced survival, resistance to 
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MAPK inhibitors (45) and these cells also displayed enrichment of CD271 expression (Figure 
2F and Suppl Figure S1I) when compared with their parental non-resistant cell lines.  
Upregulated p63 expression contributes to development of MAPKi resistance in 
melanoma. 
To investigate the impact of p63 expression in MAPKi resistant melanoma cells. Q-PCR 
analysis was performed using specific primers designed to detect all isoforms of TAp63 and 
ΔNp63 isoforms (7). TP63 mRNA expression was compared to normal primary human 
melanocytes (NHEM), which confirmed lack of detectable TA and ΔN p63 expression. Q-PCR 
analysis of TA and ΔN p63 showed an overall significant upregulation of both isoforms in all 
our melanoma MAPKi resistant cell lines (Figure 3A and Suppl figure S2A). Similar results 
were observed when p63 protein expression was measured: p63 isoforms were either 
upregulated in a cell specific manner or their expression was only increased in MAPKi 
resistant cells (Figures 3B-D and Suppl. Figure S2B). We further confirmed p63 upregulation 
at RNA and protein level in an independent panel of BRAFi-resistant melanoma cell lines 
(Figure 3A and C). 
In order to determine whether increased p63 expression is sufficient to affect cell survival we 
used RNA interference specifically targeting p63 expression in melanoma cells. Western blot 
analysis showed that both shRNA sequences reduced endogenous expression of ΔNp63β 
protein in A375M cells compared to vector control (Figure 3E). Cells depleted of p63 were 
subsequently exposed to vemurafenib demonstrating significant reduction in cell viability when 
compared with control cells (Figure 3F). Similarly, BRAFi resistant cells infected with p63 
shRNAs showed significant decrease in cell viability upon exposure to increasing doses of 
vemurafenib (Figure 3G and Suppl Figure S2C), demonstrating that reduction of p63 
expression restores sensitivity to MAPKi treatment. Reactivation of p63 expression was also 
detected in melanoma samples from patients who developed resistance to combined BRAFi 
and MEKi (figure 3H and Supp.S2D-E).  
Proteasomal degradation influences p63 stability in melanoma cells. 
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To examine regulation of p63 isoform stability in melanoma, established melanoma cell lines 
were treated with the peptide aldehyde inhibitor MG-132 (2μM) for 8h. Western blotting 
analysis showed stabilisation of endogenous p63 protein expression suggesting that 
proteasomal degradation may be one possible mechanism controlling p63 protein stability in 
melanoma cells (Figure 4A). Given the data supporting proteasome-mediated degradation of 
p63 in keratinocytes, we investigated E3-ubiquitin ligases in relation to p63 degradation in 
melanoma cells. Expression of ITCH is heterogeneous and does not always inversely 
correlate with p63 expression (Suppl Figure S3A), suggesting that its interaction with p63 in 
melanoma might only occur in a cell-type specific manner. Moreover, western blotting analysis 
showed no significant changes in ITCH expression in BRAFi resistant melanoma cell lines 
despite consistent upregulation of p63 isoforms (Suppl Figure S3B). We therefore investigated 
an alternative E3 ubiquitin ligase, namely FBXW7. Protein analysis revealed FBXW7β is the 
main isoform expressed in several established melanoma cell lines regardless of BRAF 
mutational status (Suppl Figure S3C). Isoform-specific Q-PCR analysis (alpha, beta and 
gamma FBXW7), showed significant reduction in FBXW7β isoforms in resistant cells (Figure 
4B and Suppl Figure S3D). Similarly, western blotting analysis showed significant 
downregulation of FBXW7 protein in all MAPKi resistant cells (Figure 4C-D). 
Immunofluorescence staining of FBXW7 protein in WM1158 and WM793 cells revealed that in 
both parental and BRAFi resistant cells, FBXW7β is predominantly localized to the nucleus 
(Figure 4E and Suppl Figure S3E). Sub-cellular fractionation experiments confirmed this 
nuclear localization in all melanoma cell lines, and also revealed significantly reduced 
FBXW7β expression in BRAFi resistant cells (Figure 4F). Our data therefore demonstrate that 
melanoma expresses FBXW7β protein which is mainly confined to the nucleus. 
Downregulated FBXW7 mRNA and protein in MAPKi resistant cells suggested a possible 
downstream effect of MAPK signalling on FBXW7. Pancreatic cancer samples with NRAS 
mutation displayed higher ERK activation leading to decreased FBXW7 expression with ERK 
found to directly phosphorylate FBXW7 at the Thr205 residue and regulate protein stability via 
proteasomal degradation (46). To investigate this in melanoma, A375M and WM793 
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melanoma cells were treated with vemurafenib for 24 hours. In contrast to BRAFi resistant 
cells, transient incubation of melanoma cells with vemurafenib did not show any significant 
reduction of endogenous expression of FBXW7 (Suppl Figure S3F) suggesting that FBXW7 
protein stability in melanoma cells does not rely solely on ERK phosphorylation.  
Using specific antibodies against FBXW7, immunoprecipitation experiments in few melanoma 
cell lines demonstrated direct protein interaction between endogenous ΔNp63 and FBXW7 
(Figure 4G). FBXW7 interaction occurs with all p63 isoforms (Figure 4H). To further confirm 
the direct relationship between FXBW7 and p63 protein, FBXW7 shRNAs knockdown 
experiments were performed: in A375M melanoma cells, p63 protein levels were significantly 
upregulated only in the cells with FBXW7 knockdown (Figure 4I). 
Expression and location of mdm2 influence p63/FBXW7 interaction in MAPKi treated 
melanoma  
In keratinocytes, MDM2 and FBXW7 cooperatively control stability of p63 protein following 
differentiation and UV irradiation. MDM2 transports ∆Np63 into the cytoplasm where, upon 
interaction with the phosphodegron motif of FBXW7, it undergoes proteasomal degradation 
(17). Interaction between FBXW7 and MDM2 has not been systematically assessed in any 
other cellular systems and in order to test whether this model is also relevant in melanoma, we 
examined patterns of expression and localization of MDM2 and FBXW7. Primary melanomas 
showed strong nuclear reactivity of FBXW7 in both tumour and epidermal keratinocytes, while 
MDM2 distribution was cytoplasmic and nuclear with slight reactivity within basal layer of 
epidermis (Figure 5A). To further analyse cytoplasmic and nuclear reactivity for MDM2 and 
FBXW7, 31 and 24 primary melanoma tumour nests respectively were analysed in 7 clinical 
samples. Significantly higher MDM2 reactivity was present in the cytoplasm compared to the 
nucleus, while the reverse trend was observed for FBXW7. This inverse correlation between 
MDM2 and FBXW7 expression was further observed at the gene level in a TCGA SKCM 
dataset of skin cutaneous melanoma (Suppl fig. S4A). To investigate the effect of resistance 
on MDM2 expression, mdm2 mRNA and protein levels were compared in MAPKi-sensitive 
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and resistant cell lines. Mdm2 mRNA and protein was significantly elevated in most 
established MAPKi resistant cell lines (Figure 5B-D), whereas no significant changes were 
observed in most cell lines for MDM4 (Figure 5C). MDM2 was mainly localized to the nucleus 
in immunofluorescence experiments and, in MAPKi resistant cell lines the intensity of 
fluorescence was increased significantly (Figure 5E and suppl figure S4B-C). Sub-cellular 
fractionation experiments confirmed nuclear enrichment of MDM2 expression in most MAPKi-
resistant melanoma cells (Figures 5F-G).  
To explore whether MDM2 expression and localization reflected a potential interaction with 
nuclear FBXW7 we undertook immunoprecipitation experiments in WM793, A375M melanoma 
cells and HaCaT keratinocytes which confirmed protein-protein interactions between MDM2 
and FBXW7 in melanoma cell lines (Figure 5H) and HaCaT keratinocytes. In vitro 
ubiquitylation experiment shows that mdm2 is able to increase FBXW7 ubiquitylation (Figure 
5I). To further investigate the consequence of this interaction, MDM2 was overexpressed in 
melanoma cells to test the effect on FBXW7 protein expression levels. Transfected cells were 
treated with the proteasome inhibitor MG132 (2µM) 40 hours post-transfection and cells 
harvested after 8 hours of MG132 treatment. Western blotting revealed that exogenously 
overexpressed MDM2 reduced FBXW7 protein in the absence of MG132, (Figure 5J and 
Suppl Figure S4D), and this downregulation was rescued by proteasome inhibition. The effect 
on FBXW7 was specific for MDM2 rather than MDM4 which, upon over-expression, failed to 
reduce endogenous FBXW7 (Suppl Figure S4E).  
Nutlin-3A degrades p63 expression and sensitizes MAPKi-resistant melanoma cells to 
apoptosis. 
Having established that MAPKi resistance in melanoma cells results in p63 upregulation, we 
next investigated whether p63 inhibition might restore chemosensitivity in MAPKi resistant 
cells. As few inhibitors of p63 expression are currently available, we adopted an indirect 
approach and tested the effects on p63 expression of molecules targeting other p63 
regulators. Nutlin-3A, an MDM2-p53 interaction inhibitor, induces p53 re-activation. Nutlin-3A 
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inhibits p73 interactions with MDM2 and MDM4, but does not have an inhibitory effect on TA 
and ΔNp63 (47). To test whether Nutlin-3A could affect p63 expression, MAPKi sensitive and 
resistant cells were treated with increasing doses of Nutlin-3A. There was a dose dependent 
reduction in p63 protein expression by Western blotting in most cellular model tested. In 
A375M cells, treatment with Nutlin-3A reduced ∆Np63β protein expression in a dose 
dependent manner (Suppl Figure S5A). Interestingly, Nutlin-3A was able to affect the stability 
of several p63 isoforms, as seen in the WM793 cells (Figure 6A). In addition, Nutlin-3A 
treatment also reduced all p63 isoform in WM793-PLX cells (Figure 6B) and in A375M-TR 
(Figure 6C). This is the first evidence that Nutlin-3A inhibits p63 expression in melanoma and 
N-TERT human immortalized keratinocytes (Suppl Figure S5B). Since no significant changes 
were detected at mRNA level in p63 TA and ΔN isoforms in either parental or resistant cells 
(Figure 6D, and Suppl Figure S5C), this suggests that Nutlin-3A only affects p63 protein 
stability. After Nutlin-3A treatment, most melanoma cell lines showed significant 
downregulation of ITCH protein (Suppl Figure S5D) but increased FBXW7 protein expression 
in a dose dependent manner (Figure 6E-F, Suppl Figure S5E). These observations provide 
further support for the hypothesis that p63 protein stability is specifically controlled by FBXW7 
in melanoma cells. Similarly, Nutlin-3A induced 10 and 15-fold increased transcriptional 
expression of FBXW7 mRNA in A375M and WM793 cells, respectively, particularly the 
FBXW7β isoform (Figure 6G, Suppl Figure S5F). 
Previous evidence has revealed the existence of a p53 binding site in exon 1b of the FBXW7 
promoter and expression of endogenous FBXW7β, but not FBXW7α, was previously shown to 
be induced in a p53-dependent manner (48). In order to establish whether FBXW7 
upregulation after Nutlin-3A treatment was p53-mediated, melanoma cells were transfected 
with specific siRNA against p53. In the absence of p53, Nutlin-3A had no effect on FBXW7 
expression suggesting that Nutlin-3A mediated upregulation of FBXW7 may be dependent on 
p53 stabilization (Figure 6H). This was further supported by the inability of Nutlin-3A to 
degrade p63 expression in a couple of p53 mutant melanoma cell lines (CHL-1 and SK-MEL-
28) (figure 6I and Suppl. Figure S5G). We further investigated whether the effect of mdm2 
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inhibition in melanoma cells in combination with MAPK inhibitors could synergistically increase 
cell death. Melanoma cell lines were treated with vemurafenib, Trametinib or Nutlin-3A as well 
as RG7112 and AMG232 alone or in combination. Apoptosis induction was significantly higher 
with combined treatment for 24 hours (Figure 6J and Suppl Figure S5H). Taken together, 
these data highlight the involvement of p63 upregulation in MAPKi resistance and suggest a 
potential therapeutical approach to prevent it by combining BRAF and/or MEK inhibition with 
Nutlin-3A or an alternative mdm2 inhibitory treatment. 
DISCUSSION 
We have previously reported p63 protein expression in more than 50% of melanomas 
irrespective of tumour stage (7). Here we further analysed mutational status of BRAF and 
NRAS in a subset of tumours previously scored for p63 expression establishing a statistically 
significant correlation between p63 expression and BRAF or NRAS mutation. Although our 
results raised the possibility of an association between p63 and MAPK, a direct link between 
the two signalling pathways has never been established.  
p63 upregulation has been reported in another skin malignancy - cutaneous squamous cell 
carcinoma (49-53). In keratinocytes tyrosine kinase receptor EGFR has been implicated in 
regulating ΔNp63 expression by several signalling mechanisms including via 
phosphoinositide-3-kinase (PI3K) pathway (52). Here we showed that in melanoma cells, 
ectopic overexpression of p63 isoforms in BRAF wild type cell lines in conjunction with 
knockdown of p63 in BRAFV600E mutated cell lines resulted in upregulation and 
downregulation, respectively, of the MAPK signalling cascade. Therefore, in melanoma, p63 
expression may positively affect MAPK signalling via EGFR, although further experiments are 
needed to elucidate exact mechanisms by which p63 could regulate phosphorylation of 
MEK1/2 in melanoma.  
In order to investigate the functional relevance of p63 expression on MAPKi resistance 
development, we established an in vitro model by generating BRAFi and MEKi resistant 
melanoma cell lines. To date, multiple MAPKi resistance mechanisms have been identified 
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and include emergence of NRAS or MEK mutation, drug resistant splice variant of BRAF, 
increased expression of MAP3K, COT, cyclin D1, AEBP1 and several growth factor receptors 
including IGFR, PDGFR (54-58). Once our cells acquired resistance, drastic changes in cell 
shape, plasticity and size were observed (59). Chronically treated cells become more resistant 
to BRAF or MEK inhibition with reduced apoptosis induction compared to sensitive parental 
cell lines. Similar findings have been corroborated by other groups (60). Enrichment of CD271 
was recently shown in BRAFi resistant melanoma cells (61,62). Analysis of our MAPKi 
resistant cell lines confirmed significant upregulation of CD271 expression, although with 
variation across cell lines. Aberrant activation of the MAPK signalling significantly upregulated 
p63 mRNA and protein expression in our cellular models and in 2 out of 3 clinical samples 
from patients with acquired MAPKi resistance. Whilst such observed p63 changes could be 
downstream effects of MAPKi, they may represent a driving mechanism for BRAF inhibitor 
resistance. 
We previously showed that p63 has an anti-apoptotic role in melanoma and confers 
resistance to chemotherapy (7). Depletion of p63 by RNA interference results in activation of 
p53 dependent mitochondrial apoptotic pathways, rendering melanoma cells sensitive to 
chemotherapies as well as to vemurafenib treatment. Consistent with these results, A375M 
cells depleted of p63 and treated with vemurafenib demonstrated significantly decreased cell 
survival. Furthermore, p63 depletion in BRAFi resistant cells, re-sensitized these cells to 
vemurafenib and enhanced apoptosis. These results suggest that survival role of p63 is 
enhanced in cells chronically treated with vemurafenib. 
In order to understand the impact of p63 upregulation in MAPKi resistance we explored 
regulation of p63 expression in melanoma cells. Treatment with the proteasome inhibitor 
MG132, stabilized p63 isoforms suggesting p63 stability in melanoma is controlled by an E3 
ubiquitin ligase. E3 ubiquitin ligases such as ITCH, FBXW7, WWP1 and Pirh2 have been 
extensively explored in keratinocytes and shown to regulate p63 protein and differentiation 
(11,15,16,17). Only FBXW7β was significantly reduced when E3 ubiquitin ligases expression 
were compared in MAPKi sensitive and resistant cells to identify potential regulators of p63 
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stability. In keratinocytes, MDM2 and FBXW7 can cooperatively control the stability of p63 
protein upon keratinocytes differentiation and UV irradiation. MDM2 transports ∆Np63 into the 
cytoplasm where it interacts with FBXW7 via phosphodegron motif and degrades it via 
proteasomal degradation pathway (15). More recently was shown that HDACi also reduces 
∆Np63 protein level via FBXW7 (19). Using immunoprecipitation experiments, we have 
demonstrated the endogenous interaction between p63 and FBXW7 in melanoma cells 
whereby stable depletion of FBXW7 resulted in upregulation of p63 protein.  
P53 mutations are less common in melanoma compared to other skin cancers (34,62), but 
MDM2 is often overexpressed in melanoma and recognized as one of the potential causes of 
p53 inactivity in melanoma cells (36,63,64). FBXW7 was found to be mutated in melanoma 
samples with frequent downregulation of its expression (18). Based on these observations we 
hypothesized that FBXW7 downregulation could be either the direct result of the lack of its 
transcriptional activation by p53, which is degraded by high levels of MDM2 in melanoma or 
because of a direct interaction between the two. No evidence for an interaction between 
MDM2 and FBXW7 has previously been reported for any cell type. We analysed an 
independent cohort of melanoma clinical samples (TCGA SKCM) dataset for MDM2 and 
FBXW7 mRNA expression, and the data at the gene level matched our staining expression 
pattern, confirming the inverse relationship observed in our established cell lines. Further 
analysis of MDM2 expression revealed nuclear MDM2 enrichment in MAPKi resistant cells 
and immunoprecipitation experiments confirmed endogenous interaction of MDM2 with 
FBXW7.  
To support our model, inhibition of MDM2 activity by Nutlin-3A, resulted in increased FBXW7 
expression and decreased p63 protein. Although it is possible that MDM2 overexpression 
could reduce FBXW7 protein via p53 downregulation, direct interaction between the two 
suggests that this is less likely. These results provide evidence of a previously unreported 
mechanism by which MDM2 can increase ubiquitylation activity and regulate FBXW7 protein 
stability in melanoma, ultimately affecting p63 expression.  
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Taken together, these data suggested that chronic treatment with MAPK inhibitors results in 
nuclear mdm2 enrichment with consequent FBXW7 protein downregulation. p63 accumulates 
as a result of failure of FBXW7-mediated degradation and overexpression of p63 contributes 
to increased cell survival and resistance to MAPK inhibitors (cartoon A). Although complete 
therapeutic knockdown of p63 would be challenging, indirect pharmacologic inhibition of p63 
function might reduce MAPKi resistance and potentially improve survival outcome. In this 
regard, we propose that use of nutlin-3A during treatment with MAPKi targeted therapy would 
synergistically induce apoptosis and suppress melanoma growth, thereby abrogating MAPKi 
resistance (65) (cartoon B). Our data unveil a novel survival role of p63 in melanoma and 
provide an approach to abrogate or overcome acquired resistance of melanoma to MAPK 
inhibitor targeted therapy.  
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1 M 36 Extremities (left shin) Primary T3 Positive Wild type G12D  NRAS mutated 
2 F 72 Acral (right heel) Primary T4 Positive V600E Wild type BRAF mutated 
3 F 41 Trunk (back) Primary T2 Positive V600E Wild type BRAF mutated 
4 M 82 Trunk (lower back) Primary T3 Positive V600E Wild type BRAF mutated 
5 F 47 Head / neck Primary T2 Positive V600E Wild type NRAS mutated 
6 F 79 Extremities (calf) Primary T1 Positive Wild type Wild type Wild type 
7 F 56 Trunk (chest) Primary T1 Positive Wild type Wild type Wild type 
8 M 37 Trunk (abdomen) Primary T3 Positive V600E Wild type BRAF mutated 
9 F 71 Extremities (left forearm) Primary T4 Positive V600K Wild type BRAF mutated 
10 M 83 Extremities (calf) Primary T1 Negative Wild type Wild type Wild type 
11 M 21 Extremities (calf) Primary T2 Negative Wild type Wild type Wild type 
12 M 42 Trunk (back) Primary T3 Negative Wild type Wild type Wild type 
13 M 38 Head and neck (posterior) Primary T1 Positive Wild type Q61R NRAS mutated 
14 M 43 Trunk (left clavicle) Primary T1 Negative Wild type Wild type Wild type 
15 F 79 Extremities (right arm) Primary T1 Negative Wild type Q61L NRAS mutated 
16 F 42 Extremities (left arm) Primary T2 Positive V600E Wild type BRAF mutated 
17 F 70 Extremities (right lower leg) Primary T1 Positive V600K Wild type BRAF mutated 
18 F 56 Trunk (mid back) Primary T1 Negative Wild type Wild type BRAF mutated 
19 M 65 Trunk (back) Primary T3 Negative Wild type Wild type Wild type 
20 M 68 Trunk Primary T2 Positive Wild type Q61K Wild type 
21 F 65 Extremities (right shin) Primary T3 Positive V600K Wild type NRAS mutated 
22 M 68 Head and neck Primary T1 Negative Wild type Wild type BRAF mutated 
23 F 32 Extremities (left arm) Primary T1 Positive Wild type Wild type Wild type 
24 F 67 Extremities (right arm) Recurrence  Positive V600E Wild type NRAS mutated 
25 F 65 Skin Recurrence  Negative Wild type Q61R Wild type 
26 F 60 Skin (right sole) Recurrence  Positive Wild type Wild type Wild type 
27 M 76 Skin (left foot) Recurrence  Positive Wild type Wild type Wild type 
28 M 72 Skin (left upper arm) Recurrence  Positive Wild type Q61R NRAS mutated 
29 F 64 Extremities (skin) Metastatic  Positive Wild type Q61R NRAS mutated 
30 F 57 Parotid Metastatic  Positive V600E Wild type BRAF mutated 
31 F 42 Lymph Metastatic  Negative Wild type Wild type Wild type 
32 F 50 Lymph Metastatic  Negative Wild type Wild type Wild type 
33 F 56 Skin (head and neck) Metastatic  Positive Wild type Wild type Wild type 
34 F 36 Lymph Metastatic  Negative Wild type Wild type Wild type 
35 M 37 Lymph Metastatic  Positive Wild type Wild type Wild type 
36 M 60 Lymph Metastatic  Positive Wild type Wild type Wild type 
37 F 59 Lymph (left groin) Metastatic  Positive Wild type Wild type Wild type 
38 M 74 Lymph (right axilla) Metastatic  Positive Wild type Wild type Wild type 
39 M 81 Lymph Metastatic  Positive Wild type Q61R NRAS mutated 
40 M 50 Lymph (right neck) Metastatic  Positive V600E+K601del Wild type BRAF mutated 
41 M 51 Lymph (supraclavicular) Metastatic  Positive V600E+K601del Wild type BRAF mutated 
42 F 58 Lymph (right inguinal mass) Metastatic  Positive V600E Wild type BRAF mutated 
43 F 58 Lymph (right groin) Metastatic  Negative Wild type Wild type Wild type 
44 F 77 Lymph (groin) Metastatic  Positive Wild type Q61R NRAS mutated 
45 M 52 Lymph (groin) Metastatic  Negative Wild type Wild type Wild type 
46 M 86 Lymph (axilla) Metastatic  Positive V600K  Wild type BRAF mutated 
47 F 78 Lymph Metastatic  Negative Wild type Q61R NRAS mutated 
48 M 37 Lymph (axilla) Metastatic  Positive Wild type Q61K NRAS mutated 
49 F 42 Lymph Metastatic  Negative Wild type Wild type Wild type 
50 F 57 Skin (nose) Metastatic  Negative Wild type Wild type Wild type 
 
 
Table 1. Clinical features, p63 expression and BRAF/NRAS mutational status of 
melanoma samples. BRAF/NRAS mutated samples are represented in red. p63 expression 
was established by 3 independent scorers. Positive expression was considered when p63 




Figure 1. Correlation of p63 expression and BRAF/NRAS mutational status in 
melanoma. (A) Representative images of p63 staining on primary melanoma lesions. Scale 
bar represents 50 μm magnified image scale bar. (B) 50 samples scored for % of p63 
immunohistochemistry staining by 3 independent scorers were dewaxed and processed for 
DNA extraction. Each DNA sample (50ng) was amplified for BRAF (exon 15) and for NRAS 
(exons 2 and 3) by specific PCR. Scatter plots show significant correlation between p63 
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protein expression and BRAF/NRAS mutational status. (C) Western blot analysis showing p63 
expression in different established melanoma cell lines. (D) P63 isoforms were overexpressed 
in MEL224 and LM1 cell lines. Empty vector was used as internal control. NTC stands for non-
transfected cells. Cells harvested 48 hours’ post-transfection for western blot analysis with 
p63, total and p-MEK1/2 antibodies. Similarly, A375M (E) cells infected with viral particles 
containing two different p63 shRNAs and pLKO.puro empty vector were harvested for western 
blot analysis after puromycin selection. (F) Enhancement of p-MEK1/2 expression upon 
transient expression of ∆Np63β isoform in A375M cells was abrogated by EGFR inhibitor 
(AG1478). Quantitative densitometry analysis of each protein band was normalized to GAPDH 
band. Average relative band intensity was calculated by Image Lab software from three 
independent experiments and plotted in reference to the first lane for each cell line for p-
MEK1/2, total MEK1/2 and ΔNp63β protein expression. Error bars indicate standard error 
mean. *P < 0.05, **P < 0.01, ***P < 0.001, ns < non-significant. 
Figure 2. Development and characterization of MAPKi resistant melanoma cell line. 
Established melanoma cell lines were chronically exposed to Vemurafenib or Trametinib for 8-
12 weeks until the onset of a resistant phenotype. (A) Western blot analysis of WM793 cells 
compared with BRAFi resistant cells incubated with vehicle control DMSO (-), 3µM (+), or 6µM 
PLX4032 (++) for 24 hours. GAPDH was used as loading control. Densitometry analysis of 
each protein band was normalized to GAPDH band. Average relative band intensity was 
calculated by Image Lab software from three independent experiments and plotted in 
reference to the first lane for each cell line for p-MEK1/2 and total MEK1/2 protein expression. 
(B) and (C) upper panel: Western blot analysis of A375M (B) and WM164 (C) parental 
melanoma cell line and its respective chronically MEKi treated cell line were incubated with 
vehicle control DMSO (-) or 50nM Trametinib (+) for 24 hours. Lower panel: densitometry 
analysis of p-MEK1/2 and total MEK1/2 (B) and p-ERK1/2 and total ERK1/2 (C) protein 
expression normalized to GAPDH. (D) Equal number of BRAFi sensitive and resistant cells 
was seeded in 96-well plate and treated with increasing dose of PLX4032 in triplicates for 48 
hours. After Alamar Blue staining, color change was measured with spectrophotometer. (E) 
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Growth curve of parental and MAPKi resistant melanoma cells over a period of 7-8 days. (F) 
FACS measurement of CD271 expression in MAPKi sensitive and resistant melanoma cell 
lines. The graph represents the average percentage of CD271 positive cells from three 
independent experiments. Error bars indicate standard error mean. *P < 0.05, **P < 0.01, ***P 
< 0.001, ns < non-significant. 
Figure 3. Upregulated p63 expression contributes to development of MAPKi resistance 
in melanoma. (A) QRT-PCR analysis of p63 isoforms expression in different MAPKi sensitive 
and resistant melanoma cell lines. p63 transcript levels in NHEM (Normal Human Epidermal 
Melanocyte) are also shown. GUS was used as internal control. Average fold changes from 
three independent experiments were plotted in the graph. (B), (C), (D) Western Blotting 
analysis of p63 isoforms expression in (A) A375M, (B) LM36, LM16, LM17 cell lines before 
and after the acquisition of BRAFi resistance and (C) A375M and WM164 before and after the 
acquisition of MEKi resistance. The identity of isoforms was established by their co-migration 
with exogenously expressed p63 isoforms in HEK 293T cells. GAPDH was used as a loading 
control. Densitometry analysis of each protein band was normalized to GAPDH. (E) Western 
blot analysis of A375M cells stably expressing lentiviral particles containing empty vector and 
two different shRNA sequences targeting p63 isoforms. Average relative band intensity was 
calculated ΔNp63β protein expression. (F) Measurement of cell viability in A375M cells after 
p63 knockdown and treatment with 3µM PLX4032 (G) and in BRAFi resistant melanoma cells 
depleted from p63 exposed to increasing doses of PLX4032. After 48 hours treatment cells 
were stained with crystal violet and absorbance measured with spectrophotometer. Error bars 
indicate standard error mean. *P < 0.05, **P < 0.01, ***P < 0.001, ns < non-significant. (H) 
Immunofluorescence analysis of MART1 (red) and p63 (green) expression of clinical 
melanoma sample before combined treatment with MAPKi and after acquisition of MAPKi 
resistance. Images were taken on the INCell 2200 Analyser using 15% overlapped fields 
which were then stitched together using INCell Developer Toolbox. Scale bar = 100µm in the 
2 panels and 40µm in the right enlargement, respectively. 
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Figure 4. Proteasomal degradation influences p63 stability in melanoma cells. (A) 
Western Blotting analysis of ΔNp63β expression in melanoma cell lines treated for 8 hours 
with proteasome inhibitor MG132 (2µM). GAPDH confirmed equal loading for all proteins. 
Western blot quantification is representative of three independent experiments. (B) QPCR 
analysis of specific FBXW7 isoforms (α, β and γ) in parental and MAPKi resistant melanoma 
cells. GUS was used as internal control. (C) and (D) Western blotting analysis of FBXW7 
expression in parental and MAPKi resistant melanoma cell lines. GAPDH was used as loading 
control. Average band intensity is derived from three independent experiments. (E) 
Immunofluorescence analysis of FBXW7 expression and location in parental and BRAFi 
resistant melanoma cells. Cells were imaged using the automated INCell Analyser 6000 
microscope. DAPI (blue) was used as nuclear counterstain and cell mask (grey) used as a 
whole cell dye. Scale bars represent 25µm. Experiments were performed in triplicates. (F) 
Nuclear (NER) and cytoplasmic (CYT) fractionation analysis of FBXW7 expression in parental 
and BRAFi resistant melanoma cells. GAPDH and Lamin A confirmed equal loading for 
cytoplasmic and nuclear fractions, respectively. Average band intensity from three 
independent experiments were plotted in the graph and normalized to the expression of 
GAPDH. (G) Immunoprecipitation analysis of p63 and FBXW7 endogenous interaction in 
WM1361 and A375M cells and (H) in Mel224 cells overexpressing specific p63 isoforms. (I) 
Western Blotting analysis of FBXW7 and ΔNp63β expression in A375M cells, upon ShRNA 
downregulation of FBXW7. GAPDH confirmed equal loading for all proteins. Average band 
intensity from three independent experiments were plotted in the graph and normalized to the 
expression of GAPDH. Error bars indicate standard error mean. *P < 0.05, **P < 0.01, ***P < 
0.001, ns < non-significant. 
Figure 5. Expression and location of mdm2 influence p63/FBXW7 interaction in MAPKi 
treated melanoma. (A) FBXW7 and MDM2 immunohistochemistry staining of melanoma 
clinical samples. Example of primary superficial spreading melanoma from trunk. Higher 
magnification images demonstrate nuclear FBXW7 and strong nuclear and cytoplasmic MDM2 
reactivity. Black and white scales bar represent 200μm and 100μm distance, respectively. 31 
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for MDM2 and 24 for FBXW7 primary melanoma tumour nests were scored from 7 clinical 
samples based on the cytoplasmic and nuclear immunostaining intensity. Unpaired student t-
test performed on mean expression values. ***P < 0.001. (B) QPCR analysis of MDM2 
expression in parental and BRAFi resistant melanoma cells. (C) Western blotting analysis (left 
panel) and quantification (right panel) of MDM2 and MDM4 expression in parental and BRAFi 
resistant melanoma cells. (D) QPCR (left) and Western blotting analysis (right) of MDM2 
expression in MEKi resistant melanoma cells. (E) Immunofluorescence analysis of MDM2 
expression and location in parental and BRAFi resistant melanoma cells. Scale bar = 100µm. 
Experiments were performed in triplicates and average density levels (mean pixel value 
across the cell area) are displayed in the graph. (F) and (G) Nuclear (NER) and cytoplasmic 
(CYT) fractionation analysis of FBXW7 expression in parental and BRAFi (F) or MEKi (G) 
resistant cells. GAPDH and Lamin A confirmed equal loading for cytoplasmic and nuclear 
fractions, respectively. (H) Immunoprecipitation analysis of FBXW7 and MDM2 endogenous 
interaction in melanoma cell lines and HaCaT keratinocytes. (I) Western Blotting analysis of 
FBXW7 and ubiquitin upon in vitro ubiquitylation assay with mdm2. (J) Western Blotting 
analysis and quantification of FBXW7 expression in WM793 cells, upon overexpression with 
MDM2 plasmid with or without proteasome inhibitor MG-132. Densitometry analysis of each 
protein band was normalized to GAPDH. Average relative band intensity was calculated from 
three independent experiments. *P < 0.05, **P < 0.01, ***P < 0.001, ns < non-significant. 
Figure 6. Nutlin-3A degrades p63 expression and sensitizes MAPKi resistant melanoma 
cells to apoptosis. (A), (B) Western Blotting analysis of p63 isoforms expression in WM793 
parental (A) and BRAFi resistant (B) melanoma cells treated at increasing concentration of 
Nutlin-3A. Average band intensity from three independent experiments were plotted in the 
graph and normalized to the expression of GAPDH. (C) Western Blotting analysis of p63 
expression in A375M cells Trametinib resistant treated at increasing concentration of Nutlin-
3A. (D) QPCR analysis of p63 isoforms in WM793 cells treated with increasing concentration 
of Nutlin-3A. Relative fold change was calculated with reference to the internal control, GUS. 
(E) Analysis of FBXW7 expression in WM793 cells treated with increasing concentration of 
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Nutlin-3A by Western Blotting. (F) Western Blotting analysis of FBXW7 expression in WM278 
parental as well as BRAFi resistant cells treated with 20µM Nutlin-3A. Average band intensity 
from three independent experiments were plotted in the graph and normalized to the 
expression of GAPDH. (G) QPCR analysis of FBXW7 isoforms expression in WM793 cells 
treated with 10µM Nutlin-3A. (H) Western Blotting analysis of FBXW7 expression in A375M 
cells after depletion of p53 and treatment with 10µM Nutlin-3A. (I) Western Blotting analysis of 
p63 isoforms expression in p53 mutated CHL-1 melanoma cells treated at increasing 
concentration of Nutlin-3A. (J) Measurement of apoptosis by FACS with Annexin V staining. 
Melanoma cell lines, treated for 24 hours with PLX4032 (3µM), Trametinib (50nM), Nut-3A 
(10µM), RG7112 (2.5µM), AMG232 (2.5µM) alone or combination. Graph represents the 
average percentage of total apoptotic cells from three independent experiments. Error bars 
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